Status:
UNKNOWN
Carotid Risk Prediction (CRISP) Consortium
Lead Sponsor:
Elucid Bioimaging Inc.
Collaborating Sponsors:
University of Maryland, College Park
Conditions:
Carotid Atherosclerosis
Eligibility:
All Genders
18+ years
Brief Summary
Develop adverse event prediction and plaque phenotype classification models for patients with known or suspected carotid artery disease.
Detailed Description
Develop adverse event prediction and plaque phenotype classification models using plaque morphology and composition assessment of CTA which has been validated by histology, applied to representative c...
Eligibility Criteria
Inclusion
- Subjects must have two (or more) neck CTAs at least 6 months apart of sufficient quality as documented in the vascuCAP Reading Manual.
- Atherosclerotic plaque must be visualized within the carotid artery.
Exclusion
- Subjects without visible plaque within the carotid artery
- Subject with insufficient CTA image quality (defined strictly as documented in the vascuCAP Reading Manual)
Key Trial Info
Start Date :
March 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 30 2022
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT04448353
Start Date
March 1 2019
End Date
April 30 2022
Last Update
February 4 2021
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Baltimore VA Medical Center
Baltimore, Maryland, United States, 21201
2
University of Maryland, Baltimore
Baltimore, Maryland, United States, 21201
3
Walter Reed National Military Medical Center
Bethesda, Maryland, United States, 20814
4
Weill Cornell Medicine (Affiliated with New York Presbyterian Hospital)
New York, New York, United States, 10065